Thrivent Financial for Lutherans
KRYS icon

Thrivent Financial for Lutherans’s Krystal Biotech KRYS Stock Holding History

Thrivent Financial for Lutherans’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.4M Buy
17,229
+3
+0% +$896 0.01% 870
2026
Q1 		$4.45M Sell
17,226
-508
-3% -$135K 0.01% 960
2025
Q4 		$4.37M Sell
17,734
-850
-5% -$179K 0.01% 1008
2025
Q3 		$3.28M Sell
18,584
-116
-0.6% -$17.4K 0.01% 1046
2025
Q2 		$2.57M Buy
18,700
+110
+0.6% +$16.2K 0.01% 1187
2025
Q1 		$3.35M Sell
18,590
-973
-5% -$164K 0.01% 992
2024
Q4 		$3.06M Sell
19,563
-291
-1% -$51.6K 0.01% 1160
2024
Q3 		$3.61M Sell
19,854
-771
-4% -$149K 0.01% 1083
2024
Q2 		$3.79M Buy
+20,625
New +$3.46M 0.01% 1014

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Thrivent Financial for Lutherans's KRYS Position: Q2 2026 in Review

Thrivent Financial for Lutherans increased its Krystal Biotech (KRYS) stake by 0.02% in Q2 2026, buying an estimated $896 and bringing the position to 17,229 shares worth $6.4M. The position accounts for 0.01% of the portfolio, ranked #870.

Thrivent Financial for Lutherans first reported a position in KRYS in Q2 2024 and has held it in 9 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Thrivent Financial for Lutherans held 17,229 shares of Krystal Biotech worth $6.4M as of Q2 2026.
  • Thrivent Financial for Lutherans bought 3 Krystal Biotech shares in Q2 2026, an estimated $896.
  • Krystal Biotech made up 0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #870 holding.
  • Thrivent Financial for Lutherans first reported a position in Krystal Biotech in Q2 2024 and has held it in 9 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.